Drug intelligence / Profile preview

RO7759065

Development stage: Discontinued
Lead developer: Genentech
Modality: Small Molecules
Administration: Parenteral

Overview

RO7759065 is an investigational small molecule antineoplastic agent developed by Genentech for the treatment of solid tumors, including locally advanced, recurrent, or metastatic malignant solid neoplasms. It is currently being evaluated in a Phase 1 clinical trial as both a single agent and in combination with atezolizumab (an anti-PD-L1 monoclonal antibody) to assess its safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity. The precise mechanism of action has not been publicly disclosed as of April 2025[1][2][3][4].

Beyond the preview

Go deeper on RO7759065.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO7759065.

Explore the full profile